Lung cancer specific and reduction-responsive chimaeric polymersomes for highly efficient loading of pemetrexed and targeted suppression of lung tumor in vivo
- 1 April 2018
- journal article
- research article
- Published by Elsevier in Acta Biomaterialia
- Vol. 70, 177-185
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Targeted polymeric therapeutic nanoparticles: design, development and clinical translationChemical Society Reviews, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Kidney Tubular Toxicity of Maintenance Pemetrexed TherapyAmerican Journal of Kidney Diseases, 2011
- A Novel Peptide Probe for Imaging and Targeted Delivery of Liposomal Doxorubicin to Lung TumorMolecular Pharmaceutics, 2011
- Delivering nanomedicine to solid tumorsNature Reviews Clinical Oncology, 2010
- Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2009
- Nanocarriers as an emerging platform for cancer therapyNature Nanotechnology, 2007
- Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedulesBritish Journal of Cancer, 2007
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimineJournal of Controlled Release, 2003